Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression

Patricia Sansilvestri Morel; Valerie Duvivier; Florence Bertin; Nicolas Provost; Adel Hammoutene; Edwige-Ludiwyne Hubert; Arantxa Gonzalez; Isabelle Tupinon-Mathieu; Valerie Paradis; Philippe Delerive

doi:10.1371/journal.pone.0263828

Abstract

Background and aims

Nonalcoholic Steatohepatitis (NASH) is a major cause of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma resulting ultimately in increased liver-related mortality. Fibrosis is the main driver of mortality in NASH. Procollagen C-Proteinase Enhancer-1 (PCPE-1) plays a key role in procollagen maturation and collagen fibril formation. To assess its role in liver fibrosis and NASH progression, knock-out mice were evaluated in a dietary NASH model.

Methods

Global constitutive Pcolce^-/- and WT male mice were fed with a Choline Deficient Amino acid defined High Fat Diet (CDA HFD) for 8 weeks. Liver triglycerides, steatosis, inflammation and fibrosis were assessed at histological, biochemical and gene expression levels. In addition, human liver samples from control and NASH patients were used to evaluate the expression of PCPE-1 at both mRNA and protein levels.

Results

Pcolce gene deficiency prevented diet-induced liver enlargement but not liver dysfunction. Furthermore, liver triglycerides, steatosis and inflammation were not modified in Pcolce^-/- male mice compared to WT under CDA HFD. However, a significant decrease in liver fibrosis was observed in Pcolce^-/- mice compared to WT under NASH diet, associated with a decrease in total and insoluble collagen content without any significant modifications in the expression of genes involved in fibrosis and extracellular matrix remodeling. Finally, PCPE-1 protein expression was increased in cirrhotic liver samples from both NASH and Hepatitis C patients.

Conclusions

Pcolce deficiency limits fibrosis but not NASH progression in CDA HFD fed mice.

Citation: Sansilvestri Morel P, Duvivier V, Bertin F, Provost N, Hammoutene A, Hubert E-L, et al. (2022) Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression. PLoS ONE 17(2): e0263828. https://doi.org/10.1371/journal.pone.0263828

Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), SPAIN

Received: August 5, 2021; Accepted: January 28, 2022; Published: February 11, 2022

Copyright: © 2022 Sansilvestri Morel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: Work funded by Servier.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a common and progressive disease mainly characterized by hepatic fat accumulation in the absence of alcohol consumption. NAFLD is strongly associated with obesity, metabolic syndrome, Type 2 Diabetes and dyslipidemia. NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) based on histological examination of liver biopsy and defined by the presence of inflammation and hepatocyte ballooning with various degrees of fibrosis [1, 2]. NAFLD is the most common cause of chronic liver disease worldwide with an estimated prevalence of 25%. In contrast to NAFL which is considered as a benign and reversible disease state, NASH accounts for an increased number of patients with cirrhosis, liver failure and hepatocellular carcinoma. NASH patients display an increased mortality compared to healthy population with a high cardiovascular risk. To date, there is no approved treatment for NASH. Long term follow-up studies revealed that fibrosis is the main driver of mortality in NASH [3, 4]. Fibrosis results from an excessive production of extracellular matrix (ECM) which is not balanced by degradation. From a mechanistic standpoint, it is believed that the accumulation of both triglycerides and pro-inflammatory and cytotoxic lipid oxidation side-products results in the formation of a necro-inflammatory milieu which triggers the activation of the main fibrogenic hepatic cell population, namely hepatic stellate cells (HSCs) [5]. HSCs are responsible for the deposition of the type I collagen-rich ECM and are key players in the development of NASH complications such as portal hypertension [6]. The ECM is a complex network of proteins including fibrillar and non-fibrillar collagens, glycosaminoglycans, proteoglycans and non-collagenous glycoproteins. In addition, this so-called matrisome composition may change with liver injury [7]. For instance, cross-linking of collagens makes ECM more resistant to degradation. Indeed, aging has been shown to enhance liver fibrotic response in mice through the impairment of extracellular matrix remodeling [8]. All of these studies underline the importance of better characterizing the matrisome and its remodeling during disease progression in order to identify potential drug targets.

PCPE-1(Procollagen C-Proteinase Enhancer-1, encoded by PCOLCE gene) has been described as an enhancer of BMP-1 (Bone Morphogenetic Protein-1, also named Procollagen C-Proteinase) [9], involved in the extracellular maturation of fibrillar procollagens. BMP-1 cleaves the C-terminal propeptides of fibrillar procollagens and this cleavage is a rate-limiting step in fibrogenesis, as monomers that retain C-terminal propeptides (unlike those retaining N-terminal propeptides) are not incorporated into fibrils [10]. PCPE-1 binds to C-terminal propeptides of fibrillar collagens (PICP (Procollagen type I C-terminal Propeptide) for instance) via its two CUB domains resulting in a conformational change that enhances BMP-1 activity [11, 12]. A homolog of PCPE-1, namely PCPE-2 (encoded by PCOLCE2 gene) has been described with structural similarities of CUB domains [13]. PCPE-2 also has the ability to increase the C-terminal processing of procollagen by BMP-1 [13] suggesting a role in procollagen maturation but other physiological activities have been described such as a role in cholesterol transport [14]. To date, the in vivo role of PCPE-2 still needs to be elucidated.

Several studies have described a key role of PCPE-1 in the regulation of fibrosis in different organs such as heart [15], kidney [16], lung [17] or cornea [18] injury (for a review, see [19]). Little is known about the role of PCPE-1 in the development of liver fibrosis. While PCPE-1 is not detected in freshly-isolated rat hepatocytes, liver endothelial cells or Kupffer cells, it is poorly expressed by HSCs under basal condition but strongly induced by TGF-β (Transforming Growth Factor-β) in parallel to procollagen type I synthesis [20]. Moreover, PCPE-1 expression is increased in fibrotic livers of rats treated with CCl₄ [20] suggesting that it may play a role in procollagen maturation during liver fibrogenesis. Hassoun et al. [21] have shown that plasma PCPE-1 levels in mice treated with CCl₄ increased gradually during the progression of liver fibrosis and reflected the severity of the disease. Indeed, circulating PCPE-1 is the marker that is most well-correlated with fibrosis in animals administered fibrogenic chemicals [22]. This increased level of plasma PCPE-1 was also found in patients with liver fibrosis (Hepatitis C (HCV) or B virus patients) [23, 24]. Taken together, these results suggest that PCPE-1 could be a potential fibrosis biomarker.

This study explores the role of PCPE-1 in the development of NASH and liver fibrosis. Constitutive Pcolce knock-out mice were used in the CDA HFD (Choline Deficient Amino acid defined High Fat Diet)-induced NASH model. Typical parameters of NASH (liver steatosis, inflammation, fibrosis) were evaluated and compared to control mice. Finally, PCPE-1 mRNA and protein expression levels were assessed in cirrhotic liver specimens of NASH or HCV patients.

Material and methods

Animals

Mice were maintained on a 12:12 h light/dark cycle at 21 ± 2°C and had ad libitum access to tap water and standard or NASH diet. All procedures were performed according to the ethical protocol that has been approved by the Servier Institutional Animal Care and Use Committee in accordance with the French regulations (Decree n° 2013–118 from 01 February 2013 relative to the protection of animals used for scientific purposes and 4 orders of 01 February 2013).

Wild-type C57BL/6N and Pcolce^-/- mice (8 weeks-old, male and female) were obtained from the Transgenic Department of Charles River Laboratories (France). Generation of the Pcolce^-/- mice was performed by GenOway (Lyon, France) as previously described [25].

NASH models

STAM^® model [26]: STAM liver samples were obtained from SMC Laboratories Inc. (Japan). To induce NASH, C57Bl/6J male mice were injected with streptozotocin (Sigma-Aldrich, 200 μg, subcutaneous) 2 days after birth. After weaning, mice were fed with a high fat diet (57% kcal of fat) from 4 week-old to 9 week-old. Control mice were injected with streptozotocin but were fed a standard diet from 4 to 9 week-old.

GAN DIO model (Gubra Amylin NASH Diet Induced Obese) [27]: liver samples were obtained from Gubra. (Denmark). To induce NASH, C57Bl/6J male mice were fed with standard diet or NASH-inducing diet which contains 40% saturated fat, 2% cholesterol, 22% fructose for 39 weeks.

CDA HFD (Choline Deficient Amino acid defined (0.1% methionine) High Fat Diet) model [28]: Upon arrival, male and female mice were randomly assigned to either control diet (A04 diet, SAFE) or NASH-inducing diet (A06071302, Research Diet) for 8 weeks. Mice were checked daily for health status and weighed once a week.

Western Diet model [29]: C57Bl/6J male mice (5-week-old) were purchased at Charles River Laboratories (France). Upon arrival, mice were assigned either to control diet (A04 diet, SAFE) or a NASH-inducing diet (D09100301, Research Diets), which contains 40% kcal of fat, 2% cholesterol and 20% fructose for 16 weeks.

For CDA HFD and Western Diet models, mice were anesthetized by isoflurane and livers were collected for gene expression analyses. For the CDA HFD model, blood samples were obtained from the heart cavity and livers were quickly removed, weighed and processed for histological and biochemical analyses.

Gene expression studies

Total RNA was extracted using Qiagen RNA extraction kits following manufacturer’s instructions. Total RNA was treated with DNase I (Ambion Inc., Texas, USA) at 37°C for 30 minutes, followed by inactivation at 75°C for 5 minutes. Real time quantitative PCR (RT-qPCR) assays were performed using an Applied Biosystems 7500 sequence detector. Total RNA (1 μg) was reverse transcribed with random hexamers using High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, ThermoFisher Scientific) following the manufacturer’s protocol. Gene expression levels were determined by TaqMan Fast Universal PCR Master Mix (2x), No AmpErase UNG (ref:4352042, Applied Biosystem) and 18S (Hs99999901_S1, Applied Biosystems) transcript was used as an internal control to normalize the variations for RNA amounts. No difference in 18S expression was observed between the groups (regardless of genotype or diet). Gene expression levels are expressed relative to 18S mRNA levels. The following Taqman assays were used: PCOLCE qHsaCIP0027739 (Biorad); PCOLCE2 qHsaCIP0031859 (Biorad); Pcolce qMmuCEP0056460 (Biorad); Pcolce2 qMmuCEP0052963 (Biorad); Bmp1 qMmuCEP0053968 (Biorad); Acaca Mm01304277_m1 (Applied Biosystems™); Fasn Mm00662319_m1 (Applied Biosystems™); Srebf1 Mm00550338_m1 (Applied Biosystems™); CD68 Mm00839636_g1 (Applied Biosystems™); Il1b Mm00434228_m1 (Applied Biosystems™); TNF Mm00443258_m1 (Applied Biosystems™); Acta2 Mm02546133_m1 (Applied Biosystems™); Col1a1 Mm00801666_g1 (Applied Biosystems™); Loxl2 Mm00804740_m1 (Applied Biosystems™).

Alanine AminoTransferase (ALT) and Aspartate Amino-Transferase (AST) analyses

Plasma levels of ALT and AST were determined with an automatic biochemical analyzer (Indiko Clinical Chemistry Analyzer, Thermofisher).

Liver triglyceride content

Liver samples were processed for hepatic triglyceride (TG) content. Livers were homogenized and TG content was determined using an automatic biochemical analyzer (Indiko Clinical Chemistry Analyzer) with a Triglyceride assay kit (Thermofisher).

Liver histology

Formalin-fixed, paraffin-embedded livers were sliced into 3-μm sections. Hematoxylin and Eosin (H&E) staining was performed to investigate liver histology and Picrosirius Red staining was used for liver fibrosis. NAFLD Activity Score (NAS) and fibrosis stage were determined by two double-blinded persons using the NASH CRN scoring system [30]. For hepatocellular steatosis, livers were classified into scores 0 to 3 (0: <5% of hepatocytes presenting steatosis, 1: 5 to 33% of hepatocytes presenting steatosis, 2: 34 to 66% of hepatocytes presenting steatosis and 3: > 67% of hepatocytes presenting steatosis). For inflammation, livers were scored into grades 0 to 3 (0: non inflammatory foci, 1: 1 inflammatory focus, 2: 2 to 4 inflammatory foci, 3: >4 inflammatory foci). Fibrosis was scored into stages from 0 to 4 (0: no fibrosis, 1: perisinusoidal or periportal fibrosis, 2: perisinusoidal and periportal fibrosis, 3: bridging fibrosis or septa, 4: cirrhosis).

Liver collagen quantification

Livers were collected, dried on a paper towel, carefully cut into small pieces with a scalpel and snap-frozen into liquid nitrogen before storage at -80°C. Collagen was quantified according to Baicu et al. [31]. About 80 mg of wet liver tissue were sampled and dried at 60°C. Dry tissue was ground in a glass Potter and powder was weighed. Collagen was hydrolyzed with HCl 6N (50 mg dry tissue/mL) at 110°C overnight and evaporated at 80°C for 48h. Pellets were diluted in H₂O (50 mg dry tissue/mL) and agitated for 2h at room temperature. Samples were then centrifuged 5 min at 450 g and supernatants were collected. OH-proline from tissues (and OH-proline standard (Sigma)) was then quantified by oxidation with 1 volume of chloramine T solution (0.14% (w/v) chloramine T (Sigma), 30% (v/v) ethylene glycol monomethyl ether, 50% (v/v) citrate buffer pH6) and incubated for 20 min at room temperature. Reaction was stopped by addition of 1 volume of perchloric acid 3.15M, and 1 volume of Ehrlich reagent (20% (w/v) 4-dimethylamino benzaldehyde (Sigma) in ethylene glycol) was added for 20 min at 60°C under agitation. Absorbance was then read in a spectrophotometer at 557nm.

For insoluble collagen: Tissue was diluted in NaCl 1N with proteases inhibitors (Complete Mini (Roche)) with a concentration of 50 mg dry tissue/ mL and incubated overnight at 4°C under agitation. Samples were centrifuged at 250 g for 5 min. Pellets were collected (mainly insoluble collagen) and evaporated at 80°C overnight. Hydrolyzation of insoluble collagen and OH-proline quantification were then performed as described above.

Quantity of collagen/ dry tissue weight was calculated by interpolation from OH-proline standards x 7.46 [32].

Human liver samples

Liver tissues were obtained either from patients undergoing liver resection at the digestive surgical department of Beaujon Hospital (Clichy, France) for primary or secondary liver cancer, or from the explanted liver of patients undergoing liver transplantation. Patients’ clinical information is presented in Tables 1 and 2. All patients gave a written consent to participate in the study. The study was approved by the Institutional Review Board HUPNVS, University of Paris, AP-HP (IRB n° 00006477 and declaration n° DC-2009-936). The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Liver specimens were examined by a pathologist and samples were taken from the most distal non tumoral tissue surrounding the tumoral part (for livers obtained from patients undergoing liver resection for primary or secondary liver cancer). Cirrhotic samples were obtained either from patients with metabolic syndrome or from patients with hepatitis C virus. Samples that had no abnormalities at liver histological examination were used as controls (hereafter referred as healthy liver).

Download:

Table 1. Patient’s characteristics.

Liver samples used for RT qPCR analysis.

https://doi.org/10.1371/journal.pone.0263828.t001

Download:

Table 2. Patient’s characteristics.

Liver samples used for Western blot analysis.

https://doi.org/10.1371/journal.pone.0263828.t002

Western blotting analysis of human liver samples

About 50 mg of snap frozen human tissues were homogenized in RIPA buffer containing 150 mmol/L NaCl, 50 mmol/L TrisHCl, pH 7.4, 2 mmol/L EDTA, 0.5% sodium deoxycholate, 0.2% sodium dodecyl sulfate, 2 mmol/L activated sodium orthovanadate, complete protease inhibitor cocktail tablet (Complete mini, Roche) and complete phosphatase inhibitor cocktail tablet (PhosSTOP™, Roche). Lysates were centrifuged (12,000 g, 10 min, 4°C), supernatants were collected, and protein content was quantified using the Lowry protein assay (DC™ Protein Assay, Bio-Rad). Lysates were mixed with the reducing sample buffer for electrophoresis and subsequently transferred onto nitrocellulose membrane (Bio-Rad). Equal loading was checked using Ponceau red solution. Membranes were incubated with primary antibodies (Rat anti-Human PCPE-1 antibody, R&D systems MAB2627, 1/500; Mouse anti-GAPDH antibody, Millipore MAB374, 1/20,000). After secondary antibody, immunodetection was performed using an enhanced chemiluminescence kit (Immun-Star™ WesternC™ kit, Bio-Rad). Bands were revealed using the ChemiDoc imaging system (Bio-Rad). Values reported from Western blots were obtained by band density analysis using Image Lab software (Bio-Rad) and expressed as the ratio of PCPE-1/ GAPDH. Three independent experiments were done (3 gels), and quantification was averaged for the final representation.

Statistical analysis

For comparison of 2 groups, an unpaired Student t test was used (GraphPad Prism® software, v9.0) after verification of the normal distribution of data. For more than 2 groups, a one-way analysis of variance was performed followed by a Tukey’s test. For body weight, a two-way analysis of variance was performed followed by a Tukey’s test. For the NAS histological parameters, a one-way analysis of variance with group (2 strains and 2 diets combined) as fixed effect was performed, followed a Tukey’s test (SAS software, v9.4). For the other histological parameters (scores of steatosis, inflammation and fibrosis), a Fisher exact test was performed to compare groups. Significance threshold was 5%.

Results

Liver PCPE-1 expression in different murine models of NASH

In order to address the role of PCPE-1 in the development of NASH and liver fibrosis, we first evaluated its expression in different preclinical murine models of NASH. As shown in Fig 1, liver Pcolce mRNA expression was significantly increased in STAM^TM (x1.5), Western Diet (x1.3), GAN DIO (x3.6) and CDA HFD (x4.3) models. Interestingly, PCPE-1 up-regulation was more pronounced in mice models with established fibrosis such as GAN DIO and CDA HFD models [33].

Download:

Fig 1. Evaluation of liver Pcolce mRNA gene expression in murine models of NASH.

A: STAM^TM model, control mice (n = 5), STAM mice (n = 6); B: Western diet model, control (n = 10), Western diet mice (n = 9); C: GAN DIO model (n = 3/group); D: CDA HFD after 8 weeks of diet (n = 10/group). Data are expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 vs. control mice. Unpaired t test.

https://doi.org/10.1371/journal.pone.0263828.g001

Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in Pcolce^-/- male mice

To evaluate the impact of PCPE-1 deficiency on typical NASH-associated parameters (liver steatosis, inflammation and fibrosis), the CDA HFD (8 weeks of diet) model was selected and investigated in WT and Pcolce^-/- male and female mice.

Constitutive Pcolce^-/- mice were generated as previously described [25]. Extensive phenotyping revealed that Pcolce KO mice do not display any gross abnormalities under basal conditions [25, 34]. Confirmation of Pcolce knock-out in the liver was assessed by RT-qPCR (S1 Fig). Expression of liver Pcolce2, its close homolog, was slightly but significantly (p<0.05) decreased whereas liver Bmp1 mRNA expression was not modified in Pcolce^-/- compared to WT male mice (S1 Fig).

Evaluation of body and liver weight, liver triglyceride, plasma ALT and AST levels in WT and Pcolce^-/- male mice under CDA HFD

To evaluate the impact of PCPE-1 deficiency on NASH progression and development of fibrosis, WT and Pcolce^-/- male mice were subjected to CDA-HFD for 8 weeks. As shown in Fig 2A, no body weight gain was observed during the 8 week-NASH diet for both WT and Pcolce^-/- male mice. A slightly higher body weight gain was observed in Pcolce^-/- male mice compared to male WT under control diet (Fig 2A).

Download:

Fig 2. Body and liver weight, liver TG, ALT and AST levels in WT and Pcolce^-/- male mice under A04 or CDA HFD after 8 weeks.

A: Body weight gain during A04 or CDA HFD diet (n = 12–18). ^§§§p<0.001 WT A04 vs. WT CDA HFD; °°°p<0.001 Pcolce^-/- A04 vs. Pcolce^-/- CDA HFD; *p<0.05 WT A04 vs. Pcolce^-/- A04, Two-way ANOVA with Tukey’s post-hoc analysis. B: Liver weight (n = 12–18); C: Liver triglyceride (TG) content (n = 11–16); D: Plasma Alanine Aminotransferase (ALT) level (n = 8–15); E: Plasma Aspartate Aminotransferase (AST) level (n = 8–15). Panels B-E: ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04; *p<0.05 vs. WT CDA HFD. One-way ANOVA with Tukey’s post hoc analysis. Data are expressed as mean ± SEM.

https://doi.org/10.1371/journal.pone.0263828.g002

Liver weight was significantly increased in WT male mice under CDA HFD compared to control diet (Fig 2B). Pcolce gene deficiency completely prevented this increase in liver mass (Fig 2B).

The content of liver triglyceride (TG) was similarly increased in both WT and Pcolce^-/- mice under CDA HFD (Fig 2C).

CDA HFD induced a large increase in plasma ALT levels in both WT mice and Pcolce^-/- mice, but to a lesser extent in PCPE-1 deficient mice (Fig 2D). By contrast, AST levels were significantly and similarly increased in both strains under CDA HFD (Fig 2E).

Steatosis and liver inflammation in WT and Pcolce^-/- male mice under CDA HFD

Liver steatosis and inflammation were assessed by histology and NAS score was evaluated. As shown in Fig 3, CDA HFD induced a significant increase in both liver steatosis (Fig 3A and 3C), (with 100% of mice presenting more than 66% of affected hepatocytes) and inflammation (Fig 3D) in WT male mice resulting in a significant increase of NAS score (Fig 3B). While histological results were similar in Pcolce^-/- mice under CDA HFD (Fig 3A), a slight increase in inflammation score was nevertheless observed compared to WT male mice mainly driven by a slight increase of inflammatory foci observed in Pcolce^-/- mice (Fig 3D).

Download:

Fig 3. Liver steatosis and inflammation in WT and Pcolce^-/- male mice under A04 or CDA-HFD after 8 weeks.

A: Typical examples of liver histology with Hematoxylin and Eosin staining for inflammation and steatosis analysis (bars represent 100 μm except Pcolce^-/- A04: 75 μm); B: evaluation of NAS score; C: steatosis score and D: inflammation score. Results are expressed as percentage of frequencies (C & D). NAS, steatosis and inflammation scores were determined as described in Material and Methods (n = 10–18). ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04. One-way ANOVA followed by Tukey’s post test for B. Fisher exact test for C & D.

https://doi.org/10.1371/journal.pone.0263828.g003

Liver fibrosis in WT and Pcolce^-/- male mice under CDA HFD

Fibrosis was first evaluated by histology with Picrosirius red staining of liver sections and scored. This scoring analysis was based on fibrosis localization (perisinusoidal, periportal fibrosis) or “structural” fibrosis (bridging fibrosis, septa, cirrhosis) as described in Material and Methods section. As expected, CDA HFD triggered liver fibrosis in WT male mice with the presence of both perisinusoidal and periportal fibrosis (Fig 4A and 4B). A significant decrease in liver fibrosis scoring was observed in Pcolce^-/- male mice compared to male WT under CDA HFD with a lower frequency of both perisinusoidal and periportal fibrosis (Fig 4B).

Download:

Fig 4. Liver fibrosis in WT and Pcolce^-/- male mice under A04 or CDA-HFD after 8 weeks.

A: Typical examples of liver histology with Picrosirius red staining for fibrosis (bars represent 100 μm except Pcolce^-/- A04: 75 μm). B: Fibrosis score (n = 10–18). Fibrosis score was determined as described in Material and Methods and results are expressed as percentage of frequencies. ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04; **p<0.01 vs. WT CDA HFD. Fisher exact test. C: Total collagen content in liver (n = 5–11) and D: Insoluble collagen content in liver (n = 5–12). Data are expressed as mean ± SEM. ^§§§p<0.001 vs. WT A04; *p<0.05, ***p<0.001 vs. WT CDA HFD. One-way ANOVA with Tukey’s post-test.

https://doi.org/10.1371/journal.pone.0263828.g004

Total and insoluble liver collagen were then quantified. Total collagen was significantly increased in male WT under CDA HFD (Fig 4C). Under CDA HFD, PCPE-1 deficiency protected the mice, since significantly lower total collagen content was observed in Pcolce^-/- male mice than in WT male mice (Fig 4C). To evaluate the effect of Pcolce knock-out on collagen maturation in the CDA HFD model, liver insoluble collagen was also quantified. Liver insoluble collagen was increased in WT mice under CDA HFD, and PCPE-1 deficiency induced a significant decrease of cross-linked collagens compared to WT (Fig 4D). Collagen results are consistent with histological data (Fig 4A and 4B). Taken together, these results indicate that Pcolce gene deficiency limits CDA HFD-induced liver fibrosis.

Liver mRNA expression of lipogenesis, inflammation and fibrosis genes in WT and Pcolce^-/- male mice under CDA HFD

In order to better understand from a mechanistic standpoint, the impact of Pcolce gene deficiency on NASH progression and fibrosis, gene expression studies focusing on key relevant pathways were performed. As expected, CDA HFD induced an overexpression of genes involved in de novo lipogenesis (Acetyl-CoA carboxylase 1, Fatty Acid Synthase, Sterol Regulatory Element-Binding Protein 1) in both WT and Pcolce^-/- mice, with a slightly higher expression of Acetyl-CoA carboxylase 1 in Pcolce^-/- mice (Fig 5A). The increase of inflammation markers such as CD68 (monocyte/macrophage marker), Tumor Necrosis Factor-α (TNF-α) and Interleukin 1β (IL1-β) in CDA HFD model was similar in both strains (Fig 5B). Expression of fibrosis genes such as procollagen type I, Smooth Muscle Actin and Lysyl Oxidase Like-2 (LOXL2) was also similarly increased in WT and Pcolce^-/- mice under CDA HFD (Fig 5C).

Download:

Fig 5. Liver mRNA expression of lipogenesis, inflammation and fibrosis genes in male mice under A04 or CDA HFD after 8 weeks.

Gene expression by RT-qPCR analysis in WT and Pcolce^-/- male mice (n = 9–16). A: Fatty acid/ cholesterol synthesis (Acetyl-CoA carboxylase 1 (Acaca), Fatty Acid Synthase (Fsn), Sterol regulatory element-binding protein 1 (Srebf1)). B: Inflammation (CD68, Interleukin 1β (Il1b), Tumor Necrosis Factor α (Tnf)). C: Fibrosis (Actin α2 (Acta2), procollagen type I α1 (Col1a1), Lysyl Oxidase-like-2 (Loxl2)). Data are expressed as mean ± SEM. ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04; **p<0.01 vs. WT CDA HFD. One-way ANOVA with Tukey’s post-test.

https://doi.org/10.1371/journal.pone.0263828.g005

These results indicate that Pcolce gene deficiency did not alter diet-induced expression of key genes involved in both NASH disease progression and fibrosis.

Liver parameters in WT and Pcolce^-/- female mice under CDA HFD

CDA HFD model (8 weeks of diet) was used in WT and Pcolce^-/- female mice. As shown in S2A Fig, female mice (WT and Pcolce^-/-) gradually gained body weight under CDA HFD. Liver weight and TG as well as ALT and AST levels were increased with the NASH diet, similarly in WT and Pcolce^-/- female mice (S2B–S2D Fig).

S3 Fig shows that CDA HFD induced a significant increase in both liver steatosis (S3A and S3C Fig) and inflammation (S3D Fig) in WT and Pcolce^-/- female mice resulting in a significant increase of the NAS score (S3B Fig).

Finally, CDA HFD induced liver fibrosis in WT and Pcolce^-/- female mice with the presence of both perisinusoidal and periportal fibrosis but no significant difference was observed between the 2 strains under NASH diet (S4A and S4B Fig). Interestingly, a slight decrease of liver fibrosis score was observed in Pcolce^-/- female mice compared to WT mice under control diet (S4B Fig). Total and insoluble collagen content were slightly but not significantly increased in WT mice under CDA HFD (S4C and S4D Fig). Under CDA HFD, Pcolce^-/- female mice showed a significant lower total and insoluble collagen content compared to WT mice (S4C and S4D Fig).

Expression of PCPE-1 mRNA and protein in human liver specimens

In order to assess the potential relevance of our preclinical findings, we next evaluated by RT-qPCR the hepatic expression of both PCOLCE and PCOLCE2 in patients with NASH and fibrosis (F3-F4) (Table 1). Both genes were slightly less expressed in patients with NASH and fibrosis (Fig 6A and 6B, n = 8 and 5 for control and NASH respectively). This decrease was more pronounced for PCOLCE2 even though it did not reach statistical significance. We next compared our results to previous published transcriptomic studies. Interestingly, results from 6 independent studies are in line with our findings (S1 Table). Finally, cirrhotic human liver samples were collected from NASH or HCV patients (Table 2) to evaluate PCPE-1 protein expression. All samples were scored by a pathologist. Samples without histological abnormalities were considered as controls (without steatosis, nor activity, nor fibrosis). Western blot analysis (Fig 6C, n = 4/group) showed that PCPE-1 protein expression was increased in livers of HCV patients (p<0.01) and slightly increased in liver of NASH patients but did not reach the statistical significance (p = 0.09).

Download:

Fig 6. Expression of PCOLCE and PCOLCE2 mRNA and PCPE-1 protein in human liver samples.

PCOLCE (A) and PCOLCE2 (B) mRNA expression in liver of control (n = 8) and NASH (F3-F4) patients (n = 5). PCPE-1 protein (C) in liver of control, NASH (F3-F4) and HCV cirrhotic patients (n = 4/group). One representative blot is shown, and the quantification was done from 3 independent experiments. Values reported from Western blots were obtained by band density analysis using Image Lab software (Bio-Rad) and expressed as the ratio of PCPE-1 / GAPDH. Data are expressed as mean ± SEM. **p<0.01 vs. control. Unpaired t test.

https://doi.org/10.1371/journal.pone.0263828.g006

Discussion

This study describes the effect of PCPE-1 deficiency on liver fibrosis and NASH parameters in a murine model of NASH (CDA HFD). Liver PCPE-1 expression was also assessed in human livers of control and NASH or HCV related cirrhotic patients.

PCPE-1 is a key player of fibrosis as it is involved in fibrillar collagen maturation, critical step before collagen cross-linking, more resistant to degradation. Ogata et al. [20] have described that PCPE-1 is involved in the processing of type I collagen during liver fibrinogenesis under hepatic stress conditions such as murine CCl₄ model. We thus investigated liver mRNA expression of Pcolce in different murine dietary models of NASH (STAM^TM, Western Diet, GAN DIO and CDA HFD). Liver Pcolce mRNA expression was increased in all these models, confirming the induction of liver fibrosis markers in dietary models, but interestingly, the highest increase was observed in GAN DIO and CDA HFD models, two models associated with significant fibrosis [33]. Interestingly, PCPE-1 was recently identified as part of a gene cluster involved in ECM remodeling and directly linked to fibrosis by single cell transcriptomic analysis of HSCs from mice fed with Amylin diet [35] in line with our results. To investigate the role of PCPE-1 in liver fibrosis, the CDA HFD model (8 weeks) was selected to be used with Pcolce^-/- mice. Previous studies have shown that Pcolce knock-out mice (with different constructions) do not display any phenotypic abnormalities under basal conditions [25, 34], including blood chemical chemistry such as electrolytes, hepatic enzymes, total bilirubin, creatinine or urea [25]. As expected with choline deficient and methionine defined diet, male mice fed with CDA HFD had no body weight gain, as well as an increased liver weight and strong elevation of plasma ALT and AST [28]. PCPE-1 deficiency in male mice had no impact on body weight gain, ALT (slight decrease considered as non-relevant (even statistically significant)) and AST levels suggesting that this deficiency had no impact on diet-induced liver dysfunction. Liver steatosis, as well as mRNA expression of lipogenesis markers were highly induced in the model, with no significant effect of PCPE-1 deficiency. This result was expected, as modulation of fibrosis has no impact on cellular lipid accumulation driven by the diet. As expected, CDA HFD induced an increase of liver inflammation (histology and mRNA expression of typical markers such as CD68 (monocyte/macrophage) or cytokines (TNF-α, IL1-β)). PCPE-1 deficiency did not prevent this liver inflammation and even a slight increase of inflammatory foci was observed in liver of Pcolce^-/- mice under CDA HFD which could be attributed to an infiltration of neutrophils as observed by Massoudi et al. [36] in Pcolce^-/- mouse corneas after epithelial abrasion or alkali burn. Inflammatory response stimulates the transformation of quiescent HSCs into activated HSCs, which are the main source of collagens. Indeed, CDA HFD triggered liver fibrosis in WT mice with the presence of both perisinusoidal and periportal fibrosis, as well as bridging and septa fibrosis to a lesser extent. As expected, an increased mRNA expression of fibrosis markers such as Smooth Muscle Actin, procollagen type I and LOXL-2 was observed in WT mice under CDA HFD, leading to an increased level of total and insoluble collagen content. No liver weight increase was observed in Pcolce^-/- mice under NASH diet compared to mice under standard diet. This effect might be attributed, at least in part, to a beneficial effect on liver fibrosis, as no difference was observed in hepatic TG content. Indeed, PCPE-1 deficient mice under CDA HFD displayed a significant decrease of liver fibrosis with a lower frequency of both perisinusoidal and periportal fibrosis. This result was in accordance with a decreased liver collagen content associated with a decreased insoluble collagen observed in Pcolce^-/- mice under CDA HFD. This result suggests that, in this model, the maturation of procollagen into collagen fibers is dependent on PCPE-1 which enhances BMP-1 activity and accelerates collagen maturation and deposition [10]. PCPE-1 deficiency had no impact on CDA HFD-induced mRNA expression of Smooth Muscle Actin, procollagen type I and LOXL-2, this result suggests that PCPE-1 is a distal player and does not seem to be involved in the regulation of expression of these markers, at least in this model (with 8 weeks of a NASH diet). Taken together, these results suggest that PCPE-1 deficiency decreased liver fibrosis but had no impact on NASH progression in the CDA HFD model.

Although most of the NASH preclinical models including the CDA HFD murine model have been developed and characterized using male mice [28, 37] due to sexual dimorphism associated to NAFLD [38], we also carried out similar investigations in female mice. Female mice (WT and Pcolce^-/-) gradually gained body weight under CDA HFD in contrast to males, as previously described [39]. In general, we found similar results in female mice with no impact on NASH progression and liver dysfunction upon Pcolce gene deletion. In contrast to male mice, Pcolce gene deficiency did not have a significant impact on CDA HFD-induced liver fibrosis in female mice as assessed by Picrosirius Red staining, even if no bridging fibrosis was observed in Pcolce^-/- female mice compared to WT female mice. However, we confirmed that Pcolce gene deficiency resulted in a significantly reduced total and insoluble collagen content upon CDA HFD similar to what was observed in male mice. Taken together, the data generated with female mice are consistent with the results obtained in males with an impact on liver fibrosis only.

A slight reduction in PCOLCE2 expression was observed in human liver biopsies from NASH patients compared to control. Even though PCPE-2 has been shown to play a major role in HDL-cholesterol metabolism and more broadly in reverse cholesterol transport [14, 40], it could be also involved in liver fibrosis by a direct effect on procollagen maturation or an indirect effect via cholesterol metabolism. Interestingly, PCPE-2 is mainly expressed in the heart where its role in fibrosis has been established [31]. Further studies using PCPE-2 deficient mice are required to address this point.

Hassoun et al. [23] have shown that circulating PCPE-1 is increased in patients with liver fibrosis suggesting that PCPE-1 could be a key player of liver fibrosis in patients. We thus analyzed the expression of liver PCPE-1 in patients with NASH or HCV related cirrhosis. Expression of PCOLCE mRNA was not modified in patients compared to control (confirmed by published transcriptomic studies). PCPE-1 protein expression was slightly increased in NASH patients, but not significantly (p = 0.09) likely due to the small number of samples (n = 4/group). Why PCOLCE gene expression is not up regulated in patient derived samples in contrast to all tested preclinical models, is unclear. Further studies are needed to confirm these preliminary results. Moreover, it would be of interest to assess more precisely circulating PCPE-1 levels in NASH patients with various degrees of fibrosis (as reported by Gokce and colleagues [24] in patients suffering from chronic hepatitis B) to determine whether PCPE-1 could be a diagnostic biomarker or be used to monitor efficacy of anti-fibrotic drugs. The impact of aging should also be carefully analyzed since it is well-established that NASH disease progression and development of fibrosis are also function of age [41]. It has been hypothesized that fibrosis may be less prone to reverse due to impaired fibrolysis associated with increased cross-linking of collagen fibrils [8, 42]. The role of PCPE-1 in this process should be investigated in the future.

Circumstantial evidence links the degree of fibrosis to mortality in NASH patients [43]. Therefore, there is increasing interest in pharmacologic agents that can either reverse and/or slow down the progression of fibrosis. Since the pathogenesis of NASH is complex and involves multiple pathways, a combination of pharmacological agents may be required to tackle the problem rather than a single agent. Targeting the maturation of collagen via PCPE-1 antagonism, could be a relevant strategy to act on this mechanism. Further studies are needed to explore the combination of PCPE-1 deficiency with a drug treatment targeting inflammation/ steatosis to evaluate the impact on fibrosis and NASH progression.

Supporting information

S1 Table. Pcolce and Pcolce2 expression in published transcriptomic analyses performed on NASH clinical samples.

https://doi.org/10.1371/journal.pone.0263828.s001

(DOCX)

S1 Fig. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce ^-/- male mice (18 week old, WT n = 9; Pcolce^-/- n = 12).

Data are expressed as mean ± SEM. *p<0.05, ***p<0.001 vs. WT. Unpaired t test.

https://doi.org/10.1371/journal.pone.0263828.s002

(TIF)

S2 Fig. Body and liver weight, liver TG, ALT and AST levels in WT and Pcolce^-/- female mice under A04 or CDA HFD after 8 weeks.

(A) Body weight gain during A04 or CDA HFD diet (n = 5–15). ^§§p<0.05, °°°p<0.001 vs. WT A04. 2-way ANOVA followed by Tukey’s post-hoc analysis. (B) Liver weight (n = 5–15); (C) Liver TG content (n = 5–15); (D) Plasma Alanine Aminotransferase (ALT) level (n = 2 (Pcolce^-/- A04)-11); (E) Plasma Aspartate Aminotransferase (AST) level (n = 2 (Pcolce^-/- A04)-11). ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04. Panels B-E: One-way ANOVA with Tukey’s post hoc analysis. ⁽¹⁾ For D and E, no statistical analyses and comparisons were done between Pcolce^-/- mice under A04 and CDA HFD as the number of WT mice under A04 diet was too low (n = 2). Data are expressed as mean ± SEM.

https://doi.org/10.1371/journal.pone.0263828.s003

(DOCX)

S3 Fig. Liver steatosis and inflammation in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks.

(A) Typical examples of liver histology with Hematoxylin and Eosin staining for inflammation and steatosis analysis (bars represent 75 μm); (B) evaluation of NAS score; (C) steatosis score and (D) inflammation scores. Results are expressed as percentage of frequencies (C & D). NAS, steatosis and inflammation scores were determined as described in Material and Methods (n = 5–14). ^§§§p<0.001 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04. One-way ANOVA followed by Tukey’s post test for B. Fisher exact test for C & D.

https://doi.org/10.1371/journal.pone.0263828.s004

(DOCX)

S4 Fig. Liver fibrosis in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks.

(A) Typical examples of liver histology with Picrosirius red staining for fibrosis (bars represent 75 μm). (B) Fibrosis score (n = 5–14). Fibrosis score was determined as described in Material and Methods and results are expressed as percentage of frequencies. ^§§p<0.01 vs. WT A04; °°°p<0.001 vs. Pcolce^-/- A04. Fisher exact test. (C) Total collagen content in liver (n = 3–9) and (D) Insoluble collagen content in liver (n = 5–14). Data are expressed as mean ± SEM. *p<0.05 vs. WT CDA HFD. One-way ANOVA with Tukey’s post-test.

https://doi.org/10.1371/journal.pone.0263828.s005

(DOCX)

S1 Raw images. Western blotting for analysis of PCPE-1 protein expression in human liver samples.

PCPE-1 and GAPDH protein in liver of control, NASH (F3-F4) and HCV cirrhotic patients (n = 4/group). Three independent experiments were done and are presented with Ponceau staining and with anti-PCPE1 and anti-GAPDH blotting.

https://doi.org/10.1371/journal.pone.0263828.s006

(PDF)

S1 Raw dataset. Evaluation of liver Pcolce mRNA gene expression in murine models of NASH (Fig 1).

https://doi.org/10.1371/journal.pone.0263828.s007

(PDF)

S2 Raw dataset.

Body (A) and liver weight (B), liver TG (C), ALT (D) and AST (E) levels in WT and Pcolce^-/- male mice under A04 or CDA HFD after 8 weeks (Fig 2).

https://doi.org/10.1371/journal.pone.0263828.s008

(PDF)

S3 Raw dataset.

NAS score (A), liver steatosis (B) and inflammation (C) in WT and Pcolce^-/- male mice under A04 or CDA-HFD after 8 weeks (Fig 3).

https://doi.org/10.1371/journal.pone.0263828.s009

(PDF)

S4 Raw dataset.

Liver fibrosis score (A), total collagen (B) and insoluble collagen (C) in WT and Pcolce^-/- male mice under A04 or CDA-HFD after 8 weeks (Fig 4).

https://doi.org/10.1371/journal.pone.0263828.s010

(PDF)

S5 Raw dataset.

Liver mRNA expression of lipogenesis (A), inflammation (B) and fibrosis (C) genes in male mice under A04 or CDA HFD after 8 weeks (Fig 5).

https://doi.org/10.1371/journal.pone.0263828.s011

(PDF)

S6 Raw dataset.

Expression of PCOLCE (A) and PCOLCE2 (B) mRNA and PCPE-1 protein (C) in human liver samples (Fig 6).

https://doi.org/10.1371/journal.pone.0263828.s012

(PDF)

S7 Raw dataset. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce ^-/- male mice (S1 Fig).

https://doi.org/10.1371/journal.pone.0263828.s013

(PDF)

S8 Raw dataset.

Body (A) and liver (B) weight, liver TG (C), ALT (D) and AST (E) levels in WT and Pcolce^-/- female mice under A04 or CDA HFD after 8 weeks (S2 Fig).

https://doi.org/10.1371/journal.pone.0263828.s014

(PDF)

S9 Raw dataset.

NAS score (A), liver steatosis (B) and inflammation (C) in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks (S3 Fig).

https://doi.org/10.1371/journal.pone.0263828.s015

(PDF)

S10 Raw dataset.

Liver fibrosis score (A), total collagen (B) and insoluble collagen (C) in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks (S4 Fig).

https://doi.org/10.1371/journal.pone.0263828.s016

(PDF)

Acknowledgments

We thank Mathilde Labro and Béatrice Neau from the preclinical Biostatistics department of Servier for the statistical analysis.

References

1. Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015; 1: 1–60.
- View Article
- Google Scholar
2. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017; 377: 2063–2072. pmid:29166236
- View Article
- PubMed/NCBI
- Google Scholar
3. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015; 149: 398–397. pmid:25935634
- View Article
- PubMed/NCBI
- Google Scholar
4. Hagström H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265–1273. pmid:28803953
- View Article
- PubMed/NCBI
- Google Scholar
5. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018; 15:349–364. pmid:29740166
- View Article
- PubMed/NCBI
- Google Scholar
6. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020; 158: 1913–1928. pmid:32044315
- View Article
- PubMed/NCBI
- Google Scholar
7. Massey VL, Dolin CE, Poole LG, Hudson SV, Siow DL, Brock GN, et al. The hepatic “matrisome” responds dynamically to injury: characterization of transitional changes to the extracellular matrix in mice. Hepatology. 2017; 65: 969–982. pmid:28035785
- View Article
- PubMed/NCBI
- Google Scholar
8. Delire B, Lebrun V, Selvais C, Henriet P, Bertrand A, Horsmans Y, Leclercq IA. Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling. Aging. 2016; 9: 98–113. pmid:27941216
- View Article
- PubMed/NCBI
- Google Scholar
9. Kessler E, Adar R. Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem. 1989; 186:115–121. pmid:2689170
- View Article
- PubMed/NCBI
- Google Scholar
10. Greenspan DS. Biosynthetic Processing of Collagen Molecules. In: Brinckmann J, Notbohm H, Müller PK (eds) Collagen. Topics in Current Chemistry. 2005; 247:149–183. Springer, Berlin, Heidelberg. https://doi.org/10.1007/b10382
11. Moali C, Font B, Ruggiero F, Eichenberger D, Rousselle P, François V, et al. Substrate-specific modulation of a multisubstrate proteinase. J Biol Chem. 2005; 280:24188–24194. pmid:15834133
- View Article
- PubMed/NCBI
- Google Scholar
12. Pulido D, Sharma U, Vadon-Le Goff S, Hussain SA, Cordes S, Mariano N, et al. Structural basis for the acceleration of procollagen processing by Procollagen C-Proteinase Enhancer-1. Structure. 2018; 26: 1384–1392. pmid:30078642
- View Article
- PubMed/NCBI
- Google Scholar
13. Steiglitz BM, Keene DR, Greenspan DS. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE-1. J Biol Chem. 2002; 277:49820–49830. pmid:12393877
- View Article
- PubMed/NCBI
- Google Scholar
14. Pollard RD, Blesso CN, Zabalawi M, Fulp B, Gerelus M, Zhu X, et al. Procollagen C-endopeptidase enhancer protein 2 (PCPE2) reduces atherosclerosis in mice by enhancing scavenger receptor class B1 (SR-BI)-mediated high-density lipoprotein (HDL)-cholesteryl ester uptake. J Biol Chem. 2015; 290:15496–15511. pmid:25947382
- View Article
- PubMed/NCBI
- Google Scholar
15. Kessler-Icekson G., Schlesinger H, Freimann S, Kessler E. Expression of Procollagen C-Proteinase enhancer-1 in the remodeling heart is stimulated by aldoscterone. Int J Biochem Cell Biol. 2006; 38:358–365. pmid:16300990
- View Article
- PubMed/NCBI
- Google Scholar
16. Ozkan G, Guzel S, Atar RV, Fidan C, Kara SP, Ulusoy S. Elevated serum levels of Procollagen C-Proteinase Enhancer-1 in patients with chronic kidney disease is associated with a declining glomerular filtration rate. Nephrology. 2019; 24:938–9342. pmid:30393914
- View Article
- PubMed/NCBI
- Google Scholar
17. Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T et al. Time- and compartment- resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol. 2015; 11:819–838. pmid:26174933
- View Article
- PubMed/NCBI
- Google Scholar
18. Malecaze F, Massoudi D, Fournié P, Tricoire C, Cassagne M, Malbouyres M et al. Upregulation of Bone Morphogenetic Protein-1/ mammalian tolloid and Procollagen C-Proteinase Enhancer-1 in corneal scarring. Invest Ophthalmol Vis Sci. 2014; 55:6712–6721. pmid:25249603
- View Article
- PubMed/NCBI
- Google Scholar
19. Lagoutte P, Bettler E, Vadon-Le Goff S, Moali C. Procollagen C-Proteinase Enhancer-1, a potential biomarker and therapeutic target for fibrosis. Matrix Biol Plus. 2021; 11:100062. pmid:34435180
- View Article
- PubMed/NCBI
- Google Scholar
20. Ogata I, Auster AS, Matsui A, Greenwel P, Geerts A, D’Amico T, et al. Up-regulation of type I procollagen C-proteinase enhancer protein messenger RNA in rats with CCl₄-induced liver fibrosis. Hepatology. 1997; 26:611–617. pmid:9303490
- View Article
- PubMed/NCBI
- Google Scholar
21. Hassoun E, Safrin M, Ziv H, Pri-Chen S, Kessler E. Procollagen C-proteinase enhancer 1 (PCPE-1) as a plasma marker of muscle and liver fibrosis in mice. PLOS One. 2016; 11:1–17.
- View Article
- Google Scholar
22. Ippolito DL, AbdulHameed MDM, Tawa GJ, Baer CE, Permenter MG, McDyre BC, et al. Gene expression patterns associated with histopathology in toxic liver fibrosis. Toxicol Sci. 2016; 149:67–88. pmid:26396155
- View Article
- PubMed/NCBI
- Google Scholar
23. Hassoun E, Safrin M, Wineman E, Weiss P, Kessler E. Data comparing the plasma levels of procollagen C-proteinase enhancer 1 (PCPE-1) in healthy individuals and liver fibrosis patients. Data in brief. 2017; 14:777–781. pmid:28948200
- View Article
- PubMed/NCBI
- Google Scholar
24. Gokce O, Ozenirler S, Yucel AA, Oruklu N, Esendagli GY, Karahan S. Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2018; 30:918–924. pmid:29683980
- View Article
- PubMed/NCBI
- Google Scholar
25. Sansilvestri-Morel P, Harouki-Crochemore N, Bertin F, Bertheux H, Vermeil de Conchard G, Diguet N, et al. Deficiency of procollagen C-proteinase enhancer 1 (PCPE-1) in mouse has no impact on cardiac collagen and function under basal conditions. J Cardiovasc Pharmacol. 2021; 78:e703–e713. pmid:34369899
- View Article
- PubMed/NCBI
- Google Scholar
26. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013; 46: 141–152. pmid:23430399
- View Article
- PubMed/NCBI
- Google Scholar
27. Hansen HH, Aegidius HM, Oro D, Evers SS, Heeboll S, Lykke Eriksen P, et al. Human translatability of the GAN diet-induced obese mouse model of nonalcoholic steatohepatitis. BMC Gastroenterol. 2020; 20: 210–222. pmid:32631250
- View Article
- PubMed/NCBI
- Google Scholar
28. Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Path. 2013; 94:93–103. pmid:23305254
- View Article
- PubMed/NCBI
- Google Scholar
29. Drescher HK, Weiskirchen R, Fülöp A, Hopf C, Gonzales de San Roman E, Huesgen PF, et al. The influence of different fat sources on steatohepatitis and fibrosis development in the western diet mouse model of non-alcoholic steatohepatitis (NASH). Front Physiol. 2019; 10:770. pmid:31293441
- View Article
- PubMed/NCBI
- Google Scholar
30. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313–1321. pmid:15915461
- View Article
- PubMed/NCBI
- Google Scholar
31. Baicu CF, Zhang Y, Van Laer AO, Renaud L, Zile M, Bradshaw AD. Effect of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol. 2012; 303: H234–H240. pmid:22610170
- View Article
- PubMed/NCBI
- Google Scholar
32. Neuman RE, Logan MA. The determination of collagen and elastin in tissues. J Biol Chem. 1950; 186: 549–556. pmid:14794650
- View Article
- PubMed/NCBI
- Google Scholar
33. Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of nonalcoholic fatty liver disease. J Hepatol. 2018; 68:230–237. pmid:29128391
- View Article
- PubMed/NCBI
- Google Scholar
34. Steiglitz BM, Kreider JM, Frankenburg EP, Pappano WN, Hoffman GG, Meganck JA, et al. Procollagen C proteinase enhancer 1 genes are important determinants of the mechanical properties and geometry of bone and the ultrastructure of connective tissues. Mol Cell Biol. 2006; 26:238–249. pmid:16354695
- View Article
- PubMed/NCBI
- Google Scholar
35. Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019; 75:644–660. pmid:31398325
- View Article
- PubMed/NCBI
- Google Scholar
36. Massoudi D, Germer CJ, Glisch JM, Greenspan DS. Procollagen C-Proteinase Enhancer 1 (PCPE-1) functions as an anti-angiogenic factor and enhances epithelial recovery in injured cornea. Cell Tissue Res. 2017; 370:461–476. pmid:28936615
- View Article
- PubMed/NCBI
- Google Scholar
37. Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, et al. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human diets. Biol Open. 2019; 8:1–11.
- View Article
- Google Scholar
38. Ganz M, Csak T, Szabo G. High fat diet feeding result in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol. 2014; 20:8525–8534. pmid:25024607
- View Article
- PubMed/NCBI
- Google Scholar
39. Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLOS One. 2020; 15: e0229896. pmid:32155178
- View Article
- PubMed/NCBI
- Google Scholar
40. Francone OL, Ishida BY, de la Llera-Moya M, Royer L, Happe C, Zhu J, et al. Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels. J Lipid Res. 2011; 52:1974–1983. pmid:21771977
- View Article
- PubMed/NCBI
- Google Scholar
41. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59:550–556. pmid:23665288
- View Article
- PubMed/NCBI
- Google Scholar
42. Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T, Schuppan D. Collagen and tissue turnover as a function of age: implications for fibrosis. J Hepatol. 2016; 64:103–109. pmid:26307398
- View Article
- PubMed/NCBI
- Google Scholar
43. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease; mechanisms and clinical implications. Semin Liver Dis. 2015; 35:132–145. pmid:25974899
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015; 1: 1–60.
View Article
Google Scholar

[2] View Article

[3] Google Scholar

[ref2] 2. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017; 377: 2063–2072. pmid:29166236
View Article
PubMed/NCBI
Google Scholar

[5] View Article

[6] PubMed/NCBI

[7] Google Scholar

[ref3] 3. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015; 149: 398–397. pmid:25935634
View Article
PubMed/NCBI
Google Scholar

[9] View Article

[10] PubMed/NCBI

[11] Google Scholar

[ref4] 4. Hagström H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265–1273. pmid:28803953
View Article
PubMed/NCBI
Google Scholar

[13] View Article

[14] PubMed/NCBI

[15] Google Scholar

[ref5] 5. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018; 15:349–364. pmid:29740166
View Article
PubMed/NCBI
Google Scholar

[17] View Article

[18] PubMed/NCBI

[19] Google Scholar

[ref6] 6. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020; 158: 1913–1928. pmid:32044315
View Article
PubMed/NCBI
Google Scholar

[21] View Article

[22] PubMed/NCBI

[23] Google Scholar

[ref7] 7. Massey VL, Dolin CE, Poole LG, Hudson SV, Siow DL, Brock GN, et al. The hepatic “matrisome” responds dynamically to injury: characterization of transitional changes to the extracellular matrix in mice. Hepatology. 2017; 65: 969–982. pmid:28035785
View Article
PubMed/NCBI
Google Scholar

[25] View Article

[26] PubMed/NCBI

[27] Google Scholar

[ref8] 8. Delire B, Lebrun V, Selvais C, Henriet P, Bertrand A, Horsmans Y, Leclercq IA. Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling. Aging. 2016; 9: 98–113. pmid:27941216
View Article
PubMed/NCBI
Google Scholar

[29] View Article

[30] PubMed/NCBI

[31] Google Scholar

[ref9] 9. Kessler E, Adar R. Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem. 1989; 186:115–121. pmid:2689170
View Article
PubMed/NCBI
Google Scholar

[33] View Article

[34] PubMed/NCBI

[35] Google Scholar

[ref10] 10. Greenspan DS. Biosynthetic Processing of Collagen Molecules. In: Brinckmann J, Notbohm H, Müller PK (eds) Collagen. Topics in Current Chemistry. 2005; 247:149–183. Springer, Berlin, Heidelberg. https://doi.org/10.1007/b10382

[ref11] 11. Moali C, Font B, Ruggiero F, Eichenberger D, Rousselle P, François V, et al. Substrate-specific modulation of a multisubstrate proteinase. J Biol Chem. 2005; 280:24188–24194. pmid:15834133
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref12] 12. Pulido D, Sharma U, Vadon-Le Goff S, Hussain SA, Cordes S, Mariano N, et al. Structural basis for the acceleration of procollagen processing by Procollagen C-Proteinase Enhancer-1. Structure. 2018; 26: 1384–1392. pmid:30078642
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref13] 13. Steiglitz BM, Keene DR, Greenspan DS. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE-1. J Biol Chem. 2002; 277:49820–49830. pmid:12393877
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref14] 14. Pollard RD, Blesso CN, Zabalawi M, Fulp B, Gerelus M, Zhu X, et al. Procollagen C-endopeptidase enhancer protein 2 (PCPE2) reduces atherosclerosis in mice by enhancing scavenger receptor class B1 (SR-BI)-mediated high-density lipoprotein (HDL)-cholesteryl ester uptake. J Biol Chem. 2015; 290:15496–15511. pmid:25947382
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref15] 15. Kessler-Icekson G., Schlesinger H, Freimann S, Kessler E. Expression of Procollagen C-Proteinase enhancer-1 in the remodeling heart is stimulated by aldoscterone. Int J Biochem Cell Biol. 2006; 38:358–365. pmid:16300990
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref16] 16. Ozkan G, Guzel S, Atar RV, Fidan C, Kara SP, Ulusoy S. Elevated serum levels of Procollagen C-Proteinase Enhancer-1 in patients with chronic kidney disease is associated with a declining glomerular filtration rate. Nephrology. 2019; 24:938–9342. pmid:30393914
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref17] 17. Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T et al. Time- and compartment- resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol. 2015; 11:819–838. pmid:26174933
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref18] 18. Malecaze F, Massoudi D, Fournié P, Tricoire C, Cassagne M, Malbouyres M et al. Upregulation of Bone Morphogenetic Protein-1/ mammalian tolloid and Procollagen C-Proteinase Enhancer-1 in corneal scarring. Invest Ophthalmol Vis Sci. 2014; 55:6712–6721. pmid:25249603
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref19] 19. Lagoutte P, Bettler E, Vadon-Le Goff S, Moali C. Procollagen C-Proteinase Enhancer-1, a potential biomarker and therapeutic target for fibrosis. Matrix Biol Plus. 2021; 11:100062. pmid:34435180
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref20] 20. Ogata I, Auster AS, Matsui A, Greenwel P, Geerts A, D’Amico T, et al. Up-regulation of type I procollagen C-proteinase enhancer protein messenger RNA in rats with CCl₄-induced liver fibrosis. Hepatology. 1997; 26:611–617. pmid:9303490
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref21] 21. Hassoun E, Safrin M, Ziv H, Pri-Chen S, Kessler E. Procollagen C-proteinase enhancer 1 (PCPE-1) as a plasma marker of muscle and liver fibrosis in mice. PLOS One. 2016; 11:1–17.
View Article
Google Scholar

[78] View Article

[79] Google Scholar

[ref22] 22. Ippolito DL, AbdulHameed MDM, Tawa GJ, Baer CE, Permenter MG, McDyre BC, et al. Gene expression patterns associated with histopathology in toxic liver fibrosis. Toxicol Sci. 2016; 149:67–88. pmid:26396155
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref23] 23. Hassoun E, Safrin M, Wineman E, Weiss P, Kessler E. Data comparing the plasma levels of procollagen C-proteinase enhancer 1 (PCPE-1) in healthy individuals and liver fibrosis patients. Data in brief. 2017; 14:777–781. pmid:28948200
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref24] 24. Gokce O, Ozenirler S, Yucel AA, Oruklu N, Esendagli GY, Karahan S. Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2018; 30:918–924. pmid:29683980
View Article
PubMed/NCBI
Google Scholar

[89] View Article

[90] PubMed/NCBI

[91] Google Scholar

[ref25] 25. Sansilvestri-Morel P, Harouki-Crochemore N, Bertin F, Bertheux H, Vermeil de Conchard G, Diguet N, et al. Deficiency of procollagen C-proteinase enhancer 1 (PCPE-1) in mouse has no impact on cardiac collagen and function under basal conditions. J Cardiovasc Pharmacol. 2021; 78:e703–e713. pmid:34369899
View Article
PubMed/NCBI
Google Scholar

[93] View Article

[94] PubMed/NCBI

[95] Google Scholar

[ref26] 26. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013; 46: 141–152. pmid:23430399
View Article
PubMed/NCBI
Google Scholar

[97] View Article

[98] PubMed/NCBI

[99] Google Scholar

[ref27] 27. Hansen HH, Aegidius HM, Oro D, Evers SS, Heeboll S, Lykke Eriksen P, et al. Human translatability of the GAN diet-induced obese mouse model of nonalcoholic steatohepatitis. BMC Gastroenterol. 2020; 20: 210–222. pmid:32631250
View Article
PubMed/NCBI
Google Scholar

[101] View Article

[102] PubMed/NCBI

[103] Google Scholar

[ref28] 28. Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Path. 2013; 94:93–103. pmid:23305254
View Article
PubMed/NCBI
Google Scholar

[105] View Article

[106] PubMed/NCBI

[107] Google Scholar

[ref29] 29. Drescher HK, Weiskirchen R, Fülöp A, Hopf C, Gonzales de San Roman E, Huesgen PF, et al. The influence of different fat sources on steatohepatitis and fibrosis development in the western diet mouse model of non-alcoholic steatohepatitis (NASH). Front Physiol. 2019; 10:770. pmid:31293441
View Article
PubMed/NCBI
Google Scholar

[109] View Article

[110] PubMed/NCBI

[111] Google Scholar

[ref30] 30. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313–1321. pmid:15915461
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref31] 31. Baicu CF, Zhang Y, Van Laer AO, Renaud L, Zile M, Bradshaw AD. Effect of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol. 2012; 303: H234–H240. pmid:22610170
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref32] 32. Neuman RE, Logan MA. The determination of collagen and elastin in tissues. J Biol Chem. 1950; 186: 549–556. pmid:14794650
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref33] 33. Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of nonalcoholic fatty liver disease. J Hepatol. 2018; 68:230–237. pmid:29128391
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref34] 34. Steiglitz BM, Kreider JM, Frankenburg EP, Pappano WN, Hoffman GG, Meganck JA, et al. Procollagen C proteinase enhancer 1 genes are important determinants of the mechanical properties and geometry of bone and the ultrastructure of connective tissues. Mol Cell Biol. 2006; 26:238–249. pmid:16354695
View Article
PubMed/NCBI
Google Scholar

[129] View Article

[130] PubMed/NCBI

[131] Google Scholar

[ref35] 35. Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019; 75:644–660. pmid:31398325
View Article
PubMed/NCBI
Google Scholar

[133] View Article

[134] PubMed/NCBI

[135] Google Scholar

[ref36] 36. Massoudi D, Germer CJ, Glisch JM, Greenspan DS. Procollagen C-Proteinase Enhancer 1 (PCPE-1) functions as an anti-angiogenic factor and enhances epithelial recovery in injured cornea. Cell Tissue Res. 2017; 370:461–476. pmid:28936615
View Article
PubMed/NCBI
Google Scholar

[137] View Article

[138] PubMed/NCBI

[139] Google Scholar

[ref37] 37. Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, et al. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human diets. Biol Open. 2019; 8:1–11.
View Article
Google Scholar

[141] View Article

[142] Google Scholar

[ref38] 38. Ganz M, Csak T, Szabo G. High fat diet feeding result in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol. 2014; 20:8525–8534. pmid:25024607
View Article
PubMed/NCBI
Google Scholar

[144] View Article

[145] PubMed/NCBI

[146] Google Scholar

[ref39] 39. Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLOS One. 2020; 15: e0229896. pmid:32155178
View Article
PubMed/NCBI
Google Scholar

[148] View Article

[149] PubMed/NCBI

[150] Google Scholar

[ref40] 40. Francone OL, Ishida BY, de la Llera-Moya M, Royer L, Happe C, Zhu J, et al. Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels. J Lipid Res. 2011; 52:1974–1983. pmid:21771977
View Article
PubMed/NCBI
Google Scholar

[152] View Article

[153] PubMed/NCBI

[154] Google Scholar

[ref41] 41. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59:550–556. pmid:23665288
View Article
PubMed/NCBI
Google Scholar

[156] View Article

[157] PubMed/NCBI

[158] Google Scholar

[ref42] 42. Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T, Schuppan D. Collagen and tissue turnover as a function of age: implications for fibrosis. J Hepatol. 2016; 64:103–109. pmid:26307398
View Article
PubMed/NCBI
Google Scholar

[160] View Article

[161] PubMed/NCBI

[162] Google Scholar

[ref43] 43. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease; mechanisms and clinical implications. Semin Liver Dis. 2015; 35:132–145. pmid:25974899
View Article
PubMed/NCBI
Google Scholar

[164] View Article

[165] PubMed/NCBI

[166] Google Scholar

Figures

Abstract

Background and aims

Methods

Results

Conclusions

Introduction

Material and methods

Animals

NASH models

Gene expression studies

Alanine AminoTransferase (ALT) and Aspartate Amino-Transferase (AST) analyses

Liver triglyceride content

Liver histology

Liver collagen quantification

Human liver samples

Western blotting analysis of human liver samples

Statistical analysis

Results

Liver PCPE-1 expression in different murine models of NASH

Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in Pcolce-/- male mice

Evaluation of body and liver weight, liver triglyceride, plasma ALT and AST levels in WT and Pcolce-/- male mice under CDA HFD

Steatosis and liver inflammation in WT and Pcolce-/- male mice under CDA HFD

Liver fibrosis in WT and Pcolce-/- male mice under CDA HFD

Liver mRNA expression of lipogenesis, inflammation and fibrosis genes in WT and Pcolce-/- male mice under CDA HFD

Liver parameters in WT and Pcolce-/- female mice under CDA HFD

Expression of PCPE-1 mRNA and protein in human liver specimens

Discussion

Supporting information

S1 Table. Pcolce and Pcolce2 expression in published transcriptomic analyses performed on NASH clinical samples.

S1 Fig. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce -/- male mice (18 week old, WT n = 9; Pcolce-/- n = 12).

S2 Fig. Body and liver weight, liver TG, ALT and AST levels in WT and Pcolce-/- female mice under A04 or CDA HFD after 8 weeks.

S3 Fig. Liver steatosis and inflammation in WT and Pcolce-/- female mice under A04 or CDA-HFD after 8 weeks.

S4 Fig. Liver fibrosis in WT and Pcolce-/- female mice under A04 or CDA-HFD after 8 weeks.

S1 Raw images. Western blotting for analysis of PCPE-1 protein expression in human liver samples.

S1 Raw dataset. Evaluation of liver Pcolce mRNA gene expression in murine models of NASH (Fig 1).

S7 Raw dataset. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce -/- male mice (S1 Fig).

Acknowledgments

References

Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in Pcolce^-/- male mice

Evaluation of body and liver weight, liver triglyceride, plasma ALT and AST levels in WT and Pcolce^-/- male mice under CDA HFD

Steatosis and liver inflammation in WT and Pcolce^-/- male mice under CDA HFD

Liver fibrosis in WT and Pcolce^-/- male mice under CDA HFD

Liver mRNA expression of lipogenesis, inflammation and fibrosis genes in WT and Pcolce^-/- male mice under CDA HFD

Liver parameters in WT and Pcolce^-/- female mice under CDA HFD

S1 Fig. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce ^-/- male mice (18 week old, WT n = 9; Pcolce^-/- n = 12).

S2 Fig. Body and liver weight, liver TG, ALT and AST levels in WT and Pcolce^-/- female mice under A04 or CDA HFD after 8 weeks.

S3 Fig. Liver steatosis and inflammation in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks.

S4 Fig. Liver fibrosis in WT and Pcolce^-/- female mice under A04 or CDA-HFD after 8 weeks.

S7 Raw dataset. Liver mRNA expression of Pcolce, Pcolce2 and Bmp1 in WT and Pcolce ^-/- male mice (S1 Fig).